NCT06698198View on ClinicalTrials.gov

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

PHASE1CompletedINTERVENTIONAL

Enrollment

175

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Pneumococcal Immunization

Interventions

BIOLOGICAL

Pneumococcal Conjugate Vaccine

Suspension for Intramuscular injection

BIOLOGICAL

Prevnar 13®

Suspension for Intramuscular injection

Trial Locations (2)

70427

Investigational Site Number: 0002, Metairie

07103

Investigational Site Number: 0001, Newark

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT06698198 - Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years) | Biotech Hunter | Biotech Hunter